# FOTIVDA (tivozanib): For metastatic kidney cancer FOTIVDA is the driving force to move you forward

> FOTIVDA (tivozanib) is a prescription medicine used to treat adults with metastatic kidney cancer (advanced renal cell carcinoma or aRCC) that has been treated with 2 or more prior medicines and has come back or did not respond to treatment. FOTIVDA is not a chemotherapy. It is a targeted cancer therapy that works differently by blocking the signals that tumor use to grow new blood vessels.

Official patient site providing clinical data, side effects, how to take FOTIVDA and patient support resources for FOTIVDA (tivozanib).

**Key clinical data**: 44% increase in time without tumor growth or spread (5.6 months for FOTIVDA vs. 3.9 months for sorafenib), 28% experienced no cancer growth or spread for 1 year (compared with 11% [19/175] taking sorafenib).

**Tolerability**: Almost 80% of patients were able to stay on treatment without stopping due to side effects (compared with 70% taking sorafenib) and 76% were able to take their full dose without reducing due to side effects (compared with 61% taking sorafenib).

**Possible side effects**: Most common side effects are tiredness, diarrhea, decreased appetite, nausea, hoarseness, low levels of thyroid hormones, cough, mouth sores, decreased levels of salt (sodium) and phosphate in the blood, increased levels of lipase in the blood (a blood test done to check your pancreas)

**Abbreviations**: RCC=renal cell carcinoma, TKI=tyrosine kinase inhibitor, VEGFR=vascular endothelial growth factor receptor.

## Moving Forward

- [Overview] (https://www.fotivda.com/moving-forward/): Questions to ask your healthcare team about continuing treatment for metastatic kidney cancer

## Effectiveness

- [How FOTIVDA was studied] (https://www.fotivda.com/effectiveness/):The effectiveness and safety of FOTIVDA was proven in a large clinical study of people (350 people in total) with relapsed or refractory metastatic kidney cancer where at least 2 medicines stopped working. These medicines included an immunotherapy and other treatments, including vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). During the study, 175 people with metastatic RCC were randomly chosen to take FOTIVDA and 175 were chosen to take sorafenib.

## Tolerability

-[Possible side effects] (https://www.fotivda.com/tolerability/possible-side-effects/): Possible serious side effects and most common side effects
-[Staying on therapy] (https://www.fotivda.com/tolerability/staying-on-therapy/): Almost 80% of patients were able to stay on treatment without stopping due to side effects (compared with 70% taking sorafenib) and 76% were able to take their full dose without reducing due to side effects (compared with 61% taking sorafenib).

## Taking FOTIVDA

-[Once-daily FOTIVDA fits your lifestyle] (https://www.fotivda.com/taking-fotivda/): One capsule a day, three weeks on treatment, one week off, with or without food, every 21 days followed by a 7-day break

## Patient Stories

-[Patient stories] (https://www.fotivda.com/patient-stories/): Watch real patient stories from diagnosis to treatment with FOTIVDA

## Patient Support]
-[Resources](https://www.fotivda.com/patient-support/): Overview of AVEO ACE support program, downloadable resources, patient stories
-[AVEO ACE](https://www.fotivda.com/patient-support/aveo-ace-program/) About AVEO ACE, how to enroll, support and resources, financial assistance information and frequently asked questions
-[Downloadable Resources](https://www.fotivda.com/patient-support/downloadable-resources/): Patient and Caregiver resources, brochures, treatment handbook, treatment journal, Caregiver tips

## Essential Documents

-[Full Prescribing Information](https://www.fotivda.com/fotivdapi.pdf#page=21):Complete patient information including indication, how to take FOTIVDA, possible side effects and common side effects
-[Understanding insurance coverage](https://www.fotivda.com/patient-support/aveo-ace-program/#support-and-resources)
 
---
 
*For US Patients | Contact: 1-833-FOTIVDA (1-833-368-4832) | AVEO Pharmaceuticals, Inc. | US-MAT-00044 06/26*